At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
TCK-276 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
In Brief
A Phase 1 clinical trial evaluating TCK-276 and TCK-276 Placebo for Rheumatoid Arthritis. Completed, enrolled 32 participants across 8 sites.
Detailed Summary
The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesUnited States
CollaboratorsParexel
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionJul 2023
Study CompletionJul 2023
TodayJul 2026
First PostedJun 29, 2022
Enrollment StartAug 10, 2022
Primary CompletionJul 20, 2023
Study CompletionJul 27, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.0 years ago
Interventions
TCK-276drug
Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.
TCK-276 Placebodrug
Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.